In an interview, outgoing CDC Director Mandy Cohen defended the agency’s wide focus in the face of GOP criticism that it has ...

With the drug industry’s waning interest in gene therapy, a family tries a staple of philanthropy: honorary naming.

Health care did not play a big role in the election that’s sending President Trump back to the White House and giving ...

The new administration wants “a break” from infectious disease research to focus on chronic disease. That’s impossible, ...

State officials failed to discipline Steward for regulatory violations, check its expansion plans and cost-cutting, or ...

In this week’s letters to the editor, STAT readers weigh in on the health care system, pediatrics, and mental-health apps.

The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.

"Patients will die as a result of this decision," said Gayle Pledger of the Right to Breathe advocacy campaign.

A health insurance company executive turned whistleblower, Wendell Potter thinks that the backlash to the industry is missing ...

Today's health news in STAT Morning Rounds includes HHMI's new eligibility criteria, the latest on a California bird flu ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...